Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | C1S | P09871 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374909 | 0.87 | MAPT (0.77) | MAPTPOLBGAATDP1L3MBTL1 | |
| SCHEMBL3949047 | 0.85 | PARP1 (0.57) | MAPTPOLBGAAMEN1KMT2A | |
| SCHEMBL29436991 | 0.82 | MAPT (0.69) | MAPTPOLBGAATDP1L3MBTL1 | |
| SCHEMBL9403450 | 0.82 | MAPT (0.69) | MAPTPOLBGAATDP1L3MBTL1 | |
| SCHEMBL3842568 | 0.82 | AKR1C3 (0.58) | MAPTPOLBGAAMEN1KMT2A | |
| SCHEMBL21463006 | 0.82 | PARP1 (0.53) | MAPTPOLBGAAMEN1KMT2A | |
| SCHEMBL8080314 | 0.81 | MAPT (0.67) | MAPTPOLBGAAMEN1KMT2A | |
| SCHEMBL27300542 | 0.81 | MAPT (0.67) | MAPTPOLBGAATDP1L3MBTL1 | |
| SCHEMBL8244875 | 0.81 | AKR1C3 (0.66) | MAPTPOLBGAAMEN1KMT2A | |
| SCHEMBL141641 | 0.80 | MAPT (0.71) | MAPTPOLBGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2021-05-18 | — | — | US | disclosed |
| US-10519446-B2 | Organic compounds to treat hepatitis B virus | NOVARTIS AG (CH) | 2019-12-31 | — | — | US | disclosed |
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | NOVARTIS AG (CH) | 2019-03-12 | — | — | US | disclosed |
| US-9988627-B2 | Formats for organic compounds for use in RNA interference | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988627-B2 | Formats for organic compounds for use in RNA interference | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| EP-3052107-B1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS AG (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2015051135-A2 | ORGANIC COMPOSITIONS TO TREAT HEPCIDIN-RELATED DISEASES | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051044-A2 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051366-A2 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051045-A2 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015050871-A2 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS AG (CH) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227588-B2 | 3′end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | MAPT 4049/4885POLB 1314/4885GAA 2551/4885 |
| US-11008570-B2 | 3′ end caps for RNAi agents for use in RNA interference | RNGTT, NSUN2, NSUN3 | MAPT 4049/4885POLB 1314/4885GAA 2551/4885 |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | RNGTT, NSUN2, NSUN3 | MAPT 4059/4885POLB 1302/4885GAA 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.